Tc 99m tilmanocept

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Kaposi's Sarcoma

Conditions

Kaposi's Sarcoma

Trial Timeline

Sep 1, 2014 → Oct 1, 2015

NCT ID

NCT02201420

About Tc 99m tilmanocept

Tc 99m tilmanocept is a phase 2 stage product being developed by Navidea Biopharmaceuticals for Kaposi's Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02201420. Target conditions include Kaposi's Sarcoma.

What happened to similar drugs?

1 of 1 similar drugs in Kaposi's Sarcoma were approved

Approved (1) Terminated (0) Active (0)

✅Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/TenofovirMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04078191	Phase 2	Terminated	Sep 14, 2021	Jul 9, 2024	Rheumatoid Arthritis
NCT03938636	Phase 2	Completed	Apr 8, 2019	Jun 30, 2021	Rheumatoid Arthritis
NCT02201420	Phase 2	Completed	Sep 1, 2014	Oct 1, 2015	Kaposi's Sarcoma

Competing Products

5 competing products in Kaposi's Sarcoma

See all competitors

Product	Company	Stage	Hype Score
Selumetinib	AstraZeneca	Phase 1/2	24
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir	Merck	Approved	43
Maraviroc	Pfizer	Phase 2	35
50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin	ImmunityBio	Phase 2	32
VEGF inhibitor PTC299	PTC Therapeutics	Phase 1/2	21